News

Dr. Yu Qiang: The industry will work together to wait for the flowers to bloom

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2023-03-10
  • Views:0

(Summary description)2023 is a key year for Tyco to carry forward the past and open up the future. The first domestic terfluramide, which has been put on the market, will promote the implementation of medical insurance throughout the country as soon as possible to benefit the rare patients with multiple sclerosis in China.

Dr. Yu Qiang: The industry will work together to wait for the flowers to bloom

(Summary description)2023 is a key year for Tyco to carry forward the past and open up the future. The first domestic terfluramide, which has been put on the market, will promote the implementation of medical insurance throughout the country as soon as possible to benefit the rare patients with multiple sclerosis in China.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2023-03-10
  • Views:0

2023 is a key year for CGeneTech to carry forward the past and open up the future. The first domestic terfluramide, which has been put on the market, will promote the implementation of medical insurance throughout the country as soon as possible to benefit the rare patients with multiple sclerosis in China.
At the beginning of the year, the listing application of Cetagliptin, a new DPP-4 inhibitor, has been accepted by the State Food and Drug Administration. This drug is expected to become the best hypoglycemic drug in the class. The company will make good preparations for its listing and live up to the high expectations of the industry.
At the same time, the company will also complete the Pre-IPO round of financing in order to smoothly enter the capital market and continue to promote the company's continuous innovation with sufficient funds.

Now let's listen to Dr. Yu Qiang, founder and CEO of CGeneTech, through the lens of "Magic Cube of Medicine", review the "how many storms" in 2022, and wait for the new year to "blossom on the street".

Brainstorming

Brainstorming | Exploring the Ocean of Stars through Metabolism

With the advancement of the Healthy China 2030 Plan, chronic disease drugs have become a focus of pharmaceutical research and development. Among them, the development of cardiovascular, lipid-lowering, and hypoglycemic and weight loss drugs has become a hot track in the industry. Recently, R&D clients and Haomai Technology held a "brainstorming session" in Zhuhai, focusing on clinical needs, industry trends, and the latest drug development trends in the field of metabolic diseases. Dr. Yu Qiang, founder and CEO of Shengshi Taike, attended the conference and explored the vast universe of chronic disease drugs with guests starting from metabolism.
2024-05-28
Shengshi

Shengshi Taike has once again been listed on the "Top 50 Most Influential Medical and Health Enterprises in China" list

Recently, CHC Medical Consulting and CITIC Securities officially released the "2023 China Healthcare Industry Investment and Financing Honor List". As an innovative pharmaceutical company in the commercialization stage, Shengshi Taike has once again been listed in this category and won the honor of being one of the top 50 most influential medical and health enterprises in China in 2023.
2024-05-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO